Dr Maria Victoria Mateos from Salamanca, Spain, gives ecancerTV an overview of multiple myeloma (MM) noting advances due to the introduction of novel agents, such as bortezomib, lenalidomide and pomalidomide. She outlines the improved outcomes (PFS and OS) observed with the use of combination agents, and the management of toxicities, such as thromboembotic events, with newer agents.
Dr Mateos comments on the role of stem cell transplants with the newer agents in terms of when and how agents should be used in younger and older patients. Focusing on optimisation of newer agents in older patients, Dr Mateos highlights the value of weekly vs. continuous therapy as well as low- vs. high-dose therapy.
Finally, Dr Mateos summarises her views on the leading novel agents for use in combination. With several novel drugs and on-going clinical studies, it is expected that clinical practice will change over the coming years as more data are collected. Dr Mateos encourages the entry of MM patients into future clinical trials.